Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel Free ABUS Stock Alerts

Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume

Arbutus Biopharma logo
$4.21 -0.07 (-1.64%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$4.16 -0.05 (-1.19%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Arbutus Biopharma Short Interest Overview

As of October 15, 2026, Arbutus Biopharma (ABUS) had a short interest of 24.57 million shares sold short, representing 15.48% of the public float. This marks a 27.86% decrease in short interest since the prior report. The short interest ratio (days to cover) is 4.3, meaning it would take 4.3 days of the average trading volume of 3.42 million shares to cover all short positions.

Current Short Interest
24,566,591 shares
Previous Short Interest
34,053,358 shares
Change Vs. Previous Report
-27.86%
Dollar Volume Sold Short
$105.39 million
Short Interest Ratio
4.3 Days to Cover
Last Record Date
October 15, 2026
Outstanding Shares
198,110,000 shares
Short Percent of Float
15.48%
Today's Trading Volume
2,526,175 shares
Average Trading Volume
3,423,657 shares
Today's Volume Vs. Average
74%
Short Selling Arbutus Biopharma?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Arbutus Biopharma and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

ABUS Short Interest Over Time

ABUS Days to Cover Over Time

ABUS Percentage of Float Shorted Over Time

Arbutus Biopharma Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/15/202624,566,591 shares $105.39 million -27.9%15.5%4.34 $4.29
9/30/202634,053,358 shares $162.78 million +84.2%21.5%3.53 $4.78
9/15/202618,484,910 shares $93.53 million -2.3%11.6%5.01 $5.06
8/31/202618,916,119 shares $96.09 million +2.5%11.9%3.08 $5.08
8/14/202618,456,085 shares $86.19 million -8.8%11.6%15.1 $4.67
7/31/202620,236,241 shares $87.83 million +3.0%12.8%13.69 $4.34
7/15/202619,653,287 shares $89.62 million +14.9%12.4%7.4 $4.56
6/30/202617,111,453 shares $82.13 million -2.4%10.8%4.89 $4.80
6/15/202617,522,670 shares $75.70 million +3.2%11.1%13.96 $4.32
5/29/202616,982,764 shares $77.44 million +3.3%10.7%9.18 $4.56
5/15/202616,438,082 shares $69.70 million -7.4%10.4%17.08 $4.24
4/30/202617,743,389 shares $74.52 million -0.3%11.2%7.17 $4.20
4/15/202617,803,913 shares $79.76 million +10.1%11.3%11.44 $4.48
3/31/202616,174,093 shares $72.78 million -1.4%10.2%7.04 $4.50
3/13/202616,405,599 shares $69.89 million +11.2%10.7%4.18 $4.26
2/27/202614,756,509 shares $68.77 million -1.6%9.3%9.52 $4.66
2/13/202614,998,521 shares $59.69 million +10.6%9.5%6.43 $3.98
1/30/202613,558,940 shares $56.00 million +3.8%8.8%7.47 $4.13
1/15/202613,067,041 shares $61.42 million +4.2%8.5%12.17 $4.70
12/31/202512,535,638 shares $60.30 million +16.7%8.2%8.63 $4.81
12/15/202510,740,954 shares $53.17 million -4.2%7.0%9.28 $4.95
11/28/202511,206,745 shares $49.37 million +6.1%7.3%9.87 $4.41
11/14/202510,563,698 shares $47.75 million +6.5%6.9%10.74 $4.52
10/31/20259,916,540 shares $46.91 million +0.5%6.5%10.35 $4.73
10/15/20259,860,000 shares $44.07 million -2.8%6.5%9.1 $4.47
9/30/202510,140,000 shares $46.04 million -9.1%N/A9.7 $4.54
9/15/202511,160,000 shares $50.55 million +5.8%N/A10.4 $4.53
8/31/202510,550,000 shares $39.14 million -15.7%6.9%11.5 $3.71
8/15/202512,510,000 shares $42.16 million -3.6%N/A16.1 $3.37
7/31/202512,980,000 shares $42.57 million -4.8%8.5%17.1 $3.28
7/15/202513,640,000 shares $42.69 million -0.9%N/A17.2 $3.13
6/30/202513,770,000 shares $42.55 million +7.2%9.0%15.5 $3.09
6/15/202512,840,000 shares $45.33 million +0.7%8.4%13.8 $3.53
5/31/202512,750,000 shares $42.84 million +10.9%7.0%13.5 $3.36
5/15/202511,500,000 shares $35.88 million +2.8%6.3%10.7 $3.12
4/30/202511,190,000 shares $39.72 million +1.3%N/A10.9 $3.55
4/15/202511,050,000 shares $34.92 million +12.2%6.1%11.1 $3.16
3/31/20259,850,000 shares $34.38 million +2.9%5.4%10.1 $3.49
3/15/20259,570,000 shares $31.58 million +13.8%5.3%10.9 $3.30
2/28/20258,410,000 shares $29.01 million +16.6%4.6%9.8 $3.45
Trump’s Plan To Cheat History (Ad)

China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.tc pixel

Watch Porter Stansberry's full interview and see his top pick now
2/15/20257,210,000 shares $23.72 million +7.3%4.0%8.8 $3.29
1/31/20256,720,000 shares $22.38 million +1.2%N/A8.1 $3.33
1/15/20256,640,000 shares $21.78 million +11.6%N/A8 $3.28
12/31/20245,950,000 shares $19.46 million -0.3%N/A6.8 $3.27
12/15/20245,970,000 shares $20.78 million +2.6%N/A6.9 $3.48
11/30/20245,820,000 shares $20.14 million -4.0%N/A5.7 $3.46
11/15/20246,060,000 shares $22.06 million -7.3%N/A5.3 $3.64
10/31/20246,540,000 shares $25.15 million -16.1%N/A5.9 $3.85
10/15/20247,790,000 shares $32.02 million +5.8%N/A6.9 $4.11
9/30/20247,360,000 shares $28.34 million +12.2%N/A6.6 $3.85
9/15/20246,560,000 shares $29.32 million +8.3%N/A5.6 $4.47
8/31/20246,060,000 shares $23.45 million -8.7%N/A5.8 $3.87
8/15/20246,640,000 shares $24.90 million -2.4%N/A6.6 $3.75
7/31/20246,800,000 shares $25.64 million -3.1%N/A6.8 $3.77
7/15/20247,020,000 shares $26.33 million +16.8%N/A7.3 $3.75
6/30/20246,010,000 shares $18.57 million +11.9%N/A6.1 $3.09
6/15/20245,370,000 shares $16.86 million +6.8%N/A4.2 $3.14
5/31/20245,030,000 shares $16.90 million -5.8%N/A4.1 $3.36
5/15/20245,340,000 shares $15.01 million -8.1%N/A4.6 $2.81
4/30/20245,810,000 shares $15.86 million +12.4%N/A4.3 $2.73
4/15/20245,170,000 shares $15.35 million +13.6%N/A3.7 $2.97
3/31/20244,550,000 shares $11.74 million +10.2%N/A3.4 $2.58
3/15/20244,130,000 shares $10.82 million +1.5%N/A4.4 $2.62
2/29/20244,070,000 shares $11.40 million +10.3%N/A4.2 $2.80
2/15/20243,690,000 shares $10.74 million -39.7%N/A3.8 $2.91
1/31/20246,120,000 shares $14.50 million -4.8%N/A7.3 $2.37
1/15/20246,430,000 shares $14.85 million +3.4%N/A9.5 $2.31
12/31/20236,220,000 shares $15.55 million +0.5%N/A9.1 $2.50
12/15/20236,190,000 shares $13.87 million +0.2%N/A9.2 $2.24
11/30/20236,180,000 shares $12.67 million -8.2%N/A9.4 $2.05
11/15/20236,730,000 shares $12.38 million +6.7%N/A10.6 $1.84
10/31/20236,310,000 shares $11.55 million +9.4%N/A10.4 $1.83
10/15/20235,770,000 shares $10.73 million -16.1%N/A9.4 $1.86
9/30/20236,880,000 shares $13.97 million +18.6%N/A11.2 $2.03
9/15/20235,800,000 shares $11.83 million +12.0%N/A9.4 $2.04
8/31/20235,180,000 shares $10.52 million +0.8%N/A8.3 $2.03
8/15/20235,140,000 shares $10.23 million +5.1%N/A8.4 $1.99
7/31/20234,890,000 shares $10.61 million +0.8%N/A8.5 $2.17
7/15/20234,850,000 shares $10.82 million -0.8%N/A7.8 $2.23
6/30/20234,890,000 shares $11.25 million +12.7%N/A6.8 $2.30
6/15/20234,340,000 shares $10.59 million +2.1%N/A5.8 $2.44
5/31/20234,250,000 shares $10.58 million -0.9%N/A5.3 $2.49
5/15/20234,290,000 shares $10.98 million +8.3%N/A4.7 $2.56
4/30/20233,960,000 shares $9.94 million -7.0%N/A4.2 $2.51
4/15/20234,260,000 shares $12.23 million -13.9%N/A4.7 $2.87
3/31/20234,950,000 shares $15.00 million +5.5%N/A5.4 $3.03
3/15/20234,690,000 shares $14.21 million +15.8%N/A5 $3.03
2/28/20234,050,000 shares $11.26 million +1.5%N/A4.5 $2.78
2/15/20233,990,000 shares $10.85 million -7.4%N/A4.5 $2.72
1/31/20234,310,000 shares $12.97 million -8.5%N/A4.6 $3.01
A letter from Shannon Stansberry (Ad)

Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel

Watch the full story and see the verified track record for yourself
1/15/20234,710,000 shares $13.42 million -0.6%N/A4.9 $2.85
12/30/20224,740,000 shares $11.04 million +23.1%N/A4.6 $2.33
12/15/20223,850,000 shares $10.43 million -4.0%N/A4.1 $2.71
11/30/20224,010,000 shares $9.42 million +7.2%N/A4.4 $2.35
11/15/20223,740,000 shares $10.43 million -10.3%N/A4.3 $2.79
10/31/20224,170,000 shares $9.76 million -0.7%N/A5.2 $2.34
10/15/20224,200,000 shares $9.20 million +2.2%N/A5.4 $2.19
9/30/20224,110,000 shares $7.85 million +7.6%N/A5.6 $1.91
9/15/20223,820,000 shares $8.82 million -2.6%N/A4.7 $2.31
8/31/20223,920,000 shares $8.70 million -11.1%N/A4.7 $2.22
8/15/20224,410,000 shares $11.16 million -7.4%N/A4.8 $2.53
7/31/20224,760,000 shares $11.00 million -7.4%N/A4.5 $2.31
7/15/20225,140,000 shares $13.06 million -2.5%N/A4.8 $2.54
6/30/20225,270,000 shares $14.28 million +7.1%N/A4.5 $2.71
6/15/20224,920,000 shares $12.55 million -7.9%N/A3.9 $2.55
5/31/20225,340,000 shares $12.98 million +6.6%N/A3.8 $2.43
5/15/20225,010,000 shares $11.57 million -5.8%N/A2.9 $2.31
4/30/20225,320,000 shares $12.40 million -8.3%N/A2.9 $2.33
4/15/20225,800,000 shares $15.95 million -12.8%N/A2.6 $2.75
3/31/20226,650,000 shares $19.82 million +0.3%N/A2.7 $2.98
3/15/20226,630,000 shares $18.96 million -8.8%N/A2.3 $2.86
2/28/20227,270,000 shares $23.26 million +3.0%N/A1.8 $3.20
2/15/20227,060,000 shares $22.95 million +4.1%N/A0.7 $3.25
1/31/20226,780,000 shares $19.05 million +73.0%N/A0.7 $2.81
1/15/20223,920,000 shares $12.98 million -13.9%N/A0.4 $3.31
12/31/20214,550,000 shares $17.70 million -43.6%N/A0.5 $3.89
12/15/20218,060,000 shares $32.97 million +253.5%N/A0.8 $4.09
11/30/20212,280,000 shares $7.30 million -4.2%N/A0.2 $3.20
11/15/20212,380,000 shares $8.00 million -15.0%N/A1 $3.36

ABUS Short Interest - Frequently Asked Questions

Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been covered or closed out. As of October 15th, investors have sold 24,566,591 shares of ABUS short. 15.48% of Arbutus Biopharma's shares are currently sold short. Learn More on Arbutus Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 4.3. Learn More on Arbutus Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.48% of Arbutus Biopharma's floating shares are currently sold short.

Arbutus Biopharma saw a decline in short interest since the prior report. As of October 15th, there was short interest totaling 24,566,591 shares, a decline of 27.9% from the previous total of 34,053,358 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

15.48% of Arbutus Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Arbutus Biopharma: Celcuity, Inc. (24.17%), Telix Pharmaceuticals Limited (0.10%), Viking Therapeutics, Inc. (21.41%), IDEAYA Biosciences, Inc. (10.84%), Enliven Therapeutics, Inc. (13.13%), Amylyx Pharmaceuticals, Inc. (13.35%), Parabilis Medicines, Inc. (7.49%), Denali Therapeutics Inc. (10.72%), Dyne Therapeutics, Inc. (15.06%), Nurix Therapeutics, Inc. (20.22%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($71.77 billion), Invesco QQQ ($59.70 billion), iShares Russell 2000 ETF ($23.54 billion), Medtronic PLC ($13.33 billion), SPDR S&P Biotech ETF ($10.47 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($10.36 billion), Nebius Group N.V. ($8.98 billion), iShares 20+ Year Treasury Bond ETF ($8.92 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($8.10 billion), and iShares Semiconductor ETF ($7.74 billion). View all of the most shorted stocks.

Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is October, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like ABUS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:ABUS is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 10/26/2026. FINRA publishes updated short interest twice a month.
From Our Partners
Your free stock pick for today
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...
Behind the Markets | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
The government is buying stocks
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...
Porter & Company | Sponsoredtc pixel
Cigar Lake Flooded Again Uranium Supply Shock Repeats
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
What Elon Musk's Cybercab Reveal Could Mean for Investors
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...
Brownstone Research | Sponsoredtc pixel
This little-known fund tracks gold and pays out weekly
A little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...
Investors Alley | Sponsoredtc pixel
This high yielding “gold annuity” is starting to move…
Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...
Golden Portfolio | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel